.jpeg)
2026-09-02 07:16:43
Lao Biktarvy is a generic version of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) produced in Laos for HIV-1 infection. This article explains its bioequivalence, comparison with other regimens, treatment-naïve and switch strategies, drug interactions, and monitoring.
2026-09-02 05:52:04
Finerenone is a non-steroidal selective mineralocorticoid receptor antagonist for chronic kidney disease associated with type 2 diabetes and for heart failure with LVEF ≥40%, adding a third pathway alongside RAAS and SGLT2 inhibitors.
2026-09-01 04:42:07
Selpercatinib is an oral RET inhibitor for RET fusion–positive NSCLC, thyroid cancer and other solid tumors, and RET-mutant medullary thyroid cancer. Dosing is weight-based, and acid-reducing agents require attention.
2026-09-01 04:25:06
Enasidenib is an oral small-molecule inhibitor of mutant IDH2. By lowering the oncometabolite 2-hydroxyglutarate (2-HG) and promoting myeloid differentiation, it is used in relapsed or refractory AML with an IDH2 mutation.
2026-09-01 03:28:25
Alpelisib is an oral PI3Kα inhibitor marketed as Piqray with fulvestrant for PIK3CA-mutated HR+/HER2− advanced breast cancer, and as Vijoice for PIK3CA-related overgrowth spectrum (PROS).
2026-09-01 03:18:35
Five-year OPTIC data show that response-based ponatinib dosing — starting at 45 mg and reducing to 15 mg after response — delivers durable molecular responses and long-term survival in third-line chronic-phase CML, with a markedly improved safety profile.
2026-09-01 03:12:01
Erdafitinib is an oral small-molecule FGFR tyrosine kinase inhibitor supplied as film-coated tablets, commonly available in 3 mg, 4 mg, and 5 mg strengths, with individualized dose adjustment.
2026-08-31 03:59:58
Capmatinib is a highly selective MET inhibitor for metastatic NSCLC harboring MET exon 14 skipping mutations, with efficacy established by the GEOMETRY mono-1 trial in both first-line and previously treated settings.
2026-08-31 03:37:12
The combination is approved for first-line treatment of locally advanced or metastatic NSCLC harboring EGFR exon 19 deletions or exon 21 L858R substitutions, with PFS and OS advantages over osimertinib in MARIPOSA.
2026-08-31 03:30:32
Midostaurin is an oral multi-kinase inhibitor approved for FLT3 mutation–positive newly diagnosed AML and for ASM, SM-AHN and MCL — with distinctly different dosing for each indication.
2026-08-31 03:26:31
Lapatinib is an oral reversible dual EGFR/HER2 tyrosine kinase inhibitor used in previously treated HER2-positive advanced or metastatic breast cancer to delay disease progression.
2026-08-31 03:03:03
Filgotinib (Jyseleca) is a selective JAK1 inhibitor approved overseas for moderate-to-severe rheumatoid arthritis and ulcerative colitis. This article outlines its indications, mechanism, infection risks, long-term safety, and monitoring.
